Background and importance Patients hospitalised in intensive care units (ICUs) often require the use of multiple drugs, and the intravenous (IV) route is the most common mode of administration. IV access is usually limited, leading to concomitant administration of different drugs in the same infusion line. A previous work¹ identified many administrations via a Y site without compatibility data. A list of missing data was established.

Aim and objectives From this list, we decided to evaluate the physical compatibility of two drugs frequently administered (acetylsalicylic acid and atenolol) with other drug used in ICUs by visual tests, subvisual tests and pH measurement.

Material and methods Each pair of drugs was mixed in three ratios (drug A/drug B: 9/1; 5/5; 1/9). Visual analysis, such as precipitation formation, colour change, gas formation, subvisual evaluation by UV spectrophotometry at 350, 410 and 550 nm, and pH measurements were performed for each mixture.

Results A total of 17 pairs of two drugs were tested: 10 mixtures with acetylsalicylic acid and seven mixtures with atenolol. For the mixtures with acetylsalicylic acid, eight were compatible pairs and two were incompatible pairs: acetylsalicylic acid with canreonate potassium (precipitate formation) and with Nutryelt (colouring in pink). For the mixtures with atenolol, five were compatible pairs and two were incompatible pairs: atenolol with mycophenolate (appearance of haze) and with Nutryelt (colour change).

Conclusion and relevance After laboratory tests, new incompatibilities were found which gives additional information to the literature. This study demonstrated that all mixtures were compatible except for acetylsalicylic acid with canreonate potassium and Nutryelt, and atenolol with mycophenolate and Nutryelt. However, many other mixtures should be studied due to missing data.

REFERENCES AND/OR ACKNOWLEDGEMENTS

1. D'Huart, et al. *Pharm Technol Hosp Pharm* 2019;4:29–40.

Conflict of interest No conflict of interest

3PC-071

FULLY AUTOMATED CENTRAL INTRAVENOUS ADDITIVE SERVICE (CIVAS): A 12 MONTH ANALYSIS OF PERFORMANCES AND IMPACT OF COVID-19 ON STERILE ANTIBIOTIC PRODUCTION

¹F Vagnoni*, ¹S Leoni, ¹S Guglielmi, ¹A Marinozzi, ¹C Capone, ¹F Mura, ²M Lattanzi, ¹C Cortese, ¹M Buccolini, ¹M Ragnini, ¹A Pompilio. ¹Aou Ospedali Riuniti Di Ancona, Pharmacy, Ancona, Italy; ²Loccioni, Humancare, Angeli Di Rosora, Italy

10.1136/ejhp-pharm-2021-eahpconf.46

Background and importance In 2014, the hospital pharmacy started a project to implement a central intravenous additive service (CIVAS) unit. A pre-feasibility study was performed, a new class C clean room equipped with the robotic system APOTECA unit was built and the fully automated aseptic production process was validated. In 2016, the CIVAS started producing standard doses of chemotherapy supportive treatments (palonosetron, ondansetron, dexamethasone) in ready-to-administer form for the oncology and haematology units. The production was then shifted to antibiotics (cefazolin, piperacillin-tazobactam, ceftriaxone) and pantoprazole for infectious disease, cardiac surgery and emergency medicine departments. Currently, the in-advance production of batch

preparations at CIVAS is mainly based on daily consumption and performed by one pharmacy technician and one pharmacist (0.25 full time equivalent each). The working day is from 8am to 4pm (Monday–Friday).

Aim and objectives The aim of this study was to analyse the performance of the CIVAS over the past year and evaluate the impact of the COVID-19 pandemic on the increasing demands for sterile antibiotics by emergency departments.

Material and methods Overall CIVAS production, dosage accuracy and average production time (APT) of each ready-to-administer preparation were evaluated over a period of 12 months (from September 2019 to August 2020). Data were collected from the APOTECA statistical tool.

Results 12 215 preparations were compounded, of which 26% were in syringe (1 g cefazolin, APT 125 s) and 74% in 100 mL NaCl 0.9% infusion bags (55% for 4.5 g piperacillin-tazobactam, ATP 203 s; 14% for 40 mg pantoprazole, ATP 196 s; 5% for 2 g ceftriaxone, ATP 177 s). Average dosage accuracy for all preparations was 98.9±1%. During the peak of Italy's COVID-19 outbreak (March 2020), weekly production increased by 28%. The production of pantoprazole remained steady, while piperacillin-tazobactam and ceftriaxone for the emergency departments increased considerably (+19% and 9%, respectively) and cefazolin for the cardiac surgery department decreased by 26%.

Conclusion and relevance Implementation of a fully automated CIVAS allows measuring and controlling every step of the production process for ready-to-administer preparations. The study showed that CIVAS met increasing demands for sterile antibiotics during the pandemic crisis, thereby supporting the emergency units and providing the highest level of quality and safety.

REFERENCES AND/OR ACKNOWLEDGEMENTS

1. Bufarini C. Centralised non-hazardous intravenous compounding: improvement of clinical practice. *Eur J Hosp Pharm* 2018.

Conflict of interest No conflict of interest

3PC-072

WHICH MODEL TO ESTIMATE AT BEST THE THEORETICAL OSMOLARITY OF NOMINATIVE PARENTERAL NUTRITION?

V Laurent*, C Delaunay, A Grassal, E Olivier, N Cormier. *Chu De Nantes, Pharmacotechny, Nantes, France*

10.1136/ejhp-pharm-2021-eahpconf.47

Background and importance Osmolarity is one of the pharmaceutical controls carried out on the nominative parenteral nutrition (NPN) compounded at the hospital pharmacy. A previous validation method for calculation of the theoretical osmolality of standardised parenteral nutrition (SPN) was extrapolated to NPN. Osmolarity was determined using the Pereira Da Silva equation¹ (PDS) when osmolality is >1453 mosmol/L, or the manufacturer's data (MD) equation, which is the addition of the different osmolalities of the components. After 2 years, a non-conformity osmolality rate of 8.9% was observed.

Aim and objectives The aim was to determine the best model to calculate the theoretical osmolality of the NPN to decrease the non-conformity rate.

Material and methods A retrospective analysis of the NPN osmolality values was performed on the last 27 months'